emerg
sever
acut
respiratori
syndrom
coronaviru
sarscov
middl
east
respiratori
syndrom
coronaviru
merscov
two
strain
anim
coronavirus
cross
speci
barrier
infect
caus
sever
respiratori
infect
human
within
last
year
taught
us
coronavirus
repres
global
threat
recogn
intern
border
expect
see
novel
coronavirus
emerg
futur
ideal
anim
model
reflect
clinic
sign
viral
replic
patholog
seen
human
review
present
factor
consid
establish
anim
model
studi
novel
coronavirus
compar
differ
anim
model
employ
studi
sarscov
merscov
emerg
sever
acut
respiratori
syndrom
coronaviru
sarscov
middl
east
respiratori
syndrom
coronaviru
merscov
two
strain
anim
coronavirus
cross
speci
barrier
infect
caus
sever
respiratori
infect
human
within
last
year
taught
us
coronavirus
repres
global
threat
recogn
intern
border
expect
see
novel
coronavirus
emerg
futur
ideal
anim
model
reflect
clinic
sign
viral
replic
patholog
seen
human
review
present
factor
consid
establish
anim
model
studi
novel
coronavirus
compar
differ
anim
model
employ
studi
sarscov
merscov
member
coronavirida
famili
infect
wide
rang
anim
speci
natur
limit
host
rang
human
coronavirus
includ
gener
associ
selflimit
respiratori
tract
infect
tabl
howev
past
year
two
outbreak
sever
respiratori
tract
infect
sar
mer
caus
anim
coronavirus
cross
speci
barrier
despit
sever
diseas
high
case
fatal
rate
associ
sar
mer
coronaviru
vaccin
antivir
drug
yet
avail
anim
model
need
pathogenesi
studi
well
evalu
vaccin
antivir
drug
focu
anim
model
two
coronavirus
review
coronavirus
contain
kb
long
positivesens
rna
genom
receptor
bind
domain
viral
spike
protein
sarscov
merscov
attach
angiotensinconvert
enzym
dipeptidylpeptidas
protein
respect
sar
first
report
hong
kong
went
caus
infect
approxim
casefat
rate
newli
emerg
merscov
identifi
caus
infect
associ
case
fatal
rate
approxim
center
diseas
control
prevent
confirm
first
mer
case
import
unit
state
develop
evalu
antivir
drug
vaccin
sar
mer
challeng
part
difficulti
develop
anim
model
provid
consist
reproduc
result
ideal
anim
model
one
mimic
human
diseas
share
rout
infect
increas
sever
diseas
correspond
demograph
group
compar
level
mortalitymorbid
presenc
distribut
viral
receptor
similar
human
viru
replic
select
anim
speci
correl
exist
viru
titer
diseas
sever
final
anim
model
care
assess
select
meet
experiment
goal
figur
exampl
primari
focu
elucid
pathogenesi
anim
model
fulli
replic
key
aspect
diseas
immunolog
reagent
must
avail
contrast
primari
outcom
vaccin
efficaci
studi
meaning
differ
vaccin
unvaccin
control
group
abil
vaccin
prevent
clinic
diseas
andor
patholog
associ
viral
replic
follow
challeng
provid
compel
evid
vaccin
efficaci
though
minimum
differ
challeng
viru
replic
assess
measur
vaccin
efficaci
peopl
infect
sarscov
merscov
present
initi
symptom
includ
fever
myalgia
respiratori
sign
includ
nonproduct
cough
dyspnea
chest
radiograph
abnorm
evid
almost
case
etiolog
diagnosi
made
viru
isol
cultur
polymeras
chain
reaction
assay
serolog
test
antibodi
viru
sar
associ
lung
patholog
describ
examin
postmortem
tissu
sampl
howev
patholog
chang
associ
mer
report
perhap
autopsi
rare
perform
find
sar
consist
prolong
inflamm
destruct
desquam
alveolar
pneumocyt
hyalinemembran
format
interstiti
inflammatori
infiltr
intraalveolar
hemorrhag
observ
multinucl
giant
cell
also
seen
presenc
viral
antigen
demonstr
immunohistochemistri
ihc
lung
median
age
patient
infect
sarscov
merscov
differ
merscov
tend
affect
middleag
male
sarscov
predilect
older
peopl
overal
casefat
rate
mer
greater
seen
sar
final
preexist
chronic
ill
diabet
renal
diseas
heart
diseas
less
common
sarscov
patient
nonhuman
primat
sarscov
shown
infect
rhesu
macaqu
cynomolgu
macaqu
african
green
monkey
agm
clinic
sign
viral
replic
patholog
depend
upon
speci
least
one
report
pneumon
speci
find
nonhuman
primat
nhp
variabl
like
genet
variabl
subspeci
differ
experiment
method
includ
inoculum
dose
rout
greenough
et
al
report
multiorgan
involv
fever
diarrhea
hepat
common
marmoset
infect
rhesu
macaqu
common
marmoset
merscov
result
differ
outcom
rhesu
macaqu
show
transient
pulmonari
infect
radiograph
chest
reveal
local
infiltr
interstiti
mark
clinic
ill
tabl
coronavirus
associ
diseas
human
factor
consid
select
anim
model
anim
model
tailor
goal
studi
primari
goal
elucid
pathogenesi
model
replic
key
aspect
diseas
immunolog
reagent
avail
demograph
background
eg
age
sar
anim
taken
consider
contrast
anim
model
use
vaccineantivir
efficaci
studi
must
demonstr
meaning
differ
vaccin
unvaccin
control
group
special
consider
given
anim
differ
demograph
background
respond
vaccineantivir
investig
determin
correl
protect
necessari
studi
immun
respons
vaccin
well
respons
challeng
homolog
coronaviru
may
interest
evalu
respons
challeng
coronavirus
vaccin
host
may
encount
associ
viral
replic
pneumocyt
around
termin
bronchiol
find
consist
viral
load
detect
revers
transcript
polymeras
chain
reaction
rtpcr
viral
antigen
alveolar
pneumocyt
detect
ihc
contrast
clinic
symptom
marmoset
model
much
sever
addit
bronchointerstiti
pneumonia
viral
antigen
detect
lung
marmoset
support
viral
titer
thousandfold
higher
rhesu
macaqu
anatom
physiolog
immunolog
similar
nhp
human
make
ideal
model
recapitul
pathogenesi
coronaviru
infect
human
howev
cost
limit
avail
individu
variat
among
nhp
make
difficult
conduct
studi
larg
enough
sampl
size
statist
evalu
draw
robust
conclus
despit
limit
desir
evalu
coronaviru
vaccin
candid
nhp
proceed
clinic
trial
clinic
experi
human
coronaviru
vaccin
special
consider
given
demograph
background
age
sex
sourc
presenc
copathogen
studi
carri
larg
sampl
size
order
assess
statist
signific
mice
sarscov
replic
observ
sever
inbr
strain
mice
balbc
follow
intranas
infect
mice
suscept
balbc
mice
young
inbr
mice
support
viral
replic
fail
show
clinic
sign
diseas
human
infect
sarscov
age
seem
play
import
role
diseas
suscept
mice
twelvemonthold
balbc
mice
develop
sever
diseas
young
mice
intranas
infect
older
mice
develop
weight
loss
ruffl
fur
dehydr
histopatholog
show
interstiti
pneumon
along
diffus
alveolar
damag
viral
antigen
detect
ihc
lung
older
balbc
mous
provid
opportun
studi
agedepend
suscept
human
sarscov
sever
knockout
mice
beig
also
infect
sarscov
order
determin
role
immun
effector
diseas
stat
mice
background
support
prolong
viral
replic
histopatholog
similar
human
howev
mice
target
immun
defect
limit
valu
vaccin
studi
infect
young
mice
clear
rapidli
without
clinic
diseas
addit
infect
older
mice
two
approach
employ
enhanc
clinic
sign
diseas
young
mice
develop
transgen
mice
express
human
receptor
adapt
sarscov
mice
serial
passag
mccray
et
al
demonstr
express
control
epitheli
cellspecif
promot
result
lethal
sarscov
infect
howev
sarscov
infect
mice
associ
central
nervou
system
diseas
featur
sar
human
tseng
et
al
develop
two
lineag
transgen
mice
express
cag
promot
strong
composit
promot
consist
cytomegaloviru
immedi
earli
enhanc
chicken
bactin
promot
rabbit
globulin
splice
polyadenyl
site
drive
high
level
gene
express
mammalian
express
vector
transgeneposit
mice
show
robust
viral
growth
gener
ill
tissu
patholog
infect
sarscov
lethal
lineag
mice
show
wider
spectrum
clinic
manifest
includ
death
nonleth
lineag
mice
transgen
mice
use
pathogenesi
studi
evalu
vaccin
therapeut
three
mouseadapt
strain
sarscov
develop
independ
serial
passag
sarscov
urbani
strain
respiratori
tract
mice
mouseadapt
sarscov
strain
replic
high
titer
lung
mice
associ
patholog
chang
dissemin
viru
extrapulmonari
site
mortal
diseas
mice
resembl
diseas
seen
sever
human
case
sar
three
virus
share
mutat
specif
viral
protein
replicas
nonstructur
protein
spike
glycoprotein
attest
import
protein
viral
pathogenesi
infect
older
mice
viru
produc
clinic
diseas
particularli
reminisc
acut
respiratori
distress
syndrom
ard
human
contrast
sarscov
mice
natur
suscept
infect
merscov
mous
receptor
differ
human
crucial
area
interact
merscov
spike
protein
balbc
mice
transduc
adenovir
vector
express
mice
support
replic
merscov
associ
interstiti
pneumonia
viral
antigen
lung
older
transduc
mice
lost
weight
mortal
observ
agraw
et
al
recent
develop
transgen
mous
model
global
express
control
cag
promot
use
gener
sar
transgen
mice
mice
fulli
permiss
merscov
infect
support
robust
infect
sever
respiratori
gener
ill
led
death
within
day
infect
high
viral
titer
recov
multipl
organ
patholog
chang
consist
extens
inflamm
mous
model
avail
use
evalu
pathogenesi
virus
test
vaccin
antivir
drug
mice
advantag
due
low
cost
small
size
avail
also
manipul
genet
level
immunolog
reagent
avail
studi
viral
pathogenesi
golden
syrian
hamster
excel
model
sarscov
viru
replic
high
titer
lung
associ
patholog
follow
intranas
inocul
sarscov
viral
replic
observ
upper
lower
respiratori
tract
peak
replic
three
day
infect
viru
clear
seven
ten
day
infect
viral
replic
accompani
pronounc
histopatholog
chang
lung
includ
interstiti
inflamm
pneumon
consolid
sinc
hamster
show
outward
sign
clinic
ill
exercis
wheel
nalgen
activ
wheel
employ
measur
activ
revolutionsnight
activ
wheel
show
sarscov
infect
hamster
less
activ
day
two
seven
postinfect
primari
infect
elicit
neutral
antibodi
respons
provid
protect
subsequ
infect
hamster
suitabl
immunoprophylaxi
treatment
studi
object
clinic
sign
accompani
high
viral
titer
pulmonari
histopatholog
attempt
experiment
infect
hamster
merscov
success
ferret
frequent
use
model
studi
respiratori
virus
infect
human
howev
conflict
data
report
ferret
infect
sarscov
one
group
observ
clinic
ill
anoth
group
ferret
model
character
resolv
inconsist
result
fever
sneez
associ
high
viral
titer
upper
respiratori
tract
histolog
chang
lung
character
lymphohistiocyt
bronchointerstiti
pneumonia
ferret
support
replic
merscov
applic
anim
model
vaccin
develop
sarscov
merscov
research
demonstr
singl
anim
speci
serv
model
coronavirus
tabl
abil
elicit
clinic
diseas
viral
replic
patholog
depend
express
viral
receptor
speci
demograph
characterist
anim
infect
young
mice
sarscov
ideal
limit
histopatholog
clinic
diseas
howev
combin
two
approach
use
anim
model
viral
diseas
tabl
clinic
sign
viral
replic
patholog
sarscov
merscov
human
variou
anim
model
human
clinic
sign
includ
fever
respiratori
ill
lung
patholog
consist
pneumonia
acut
lung
injuri
clinic
sign
includ
fever
respiratori
ill
patient
develop
renal
failur
lung
patholog
sampl
avail
investig
nhp
rhesu
macaqu
cynomolgu
macaqu
african
green
monkey
common
marmoset
suscept
infect
clinic
sign
viral
replic
patholog
depend
speci
common
marmoset
sever
respons
viru
higher
viral
titer
sever
patholog
lung
lethal
also
observ
model
young
inbr
mice
balbc
support
viral
replic
fail
show
clinic
sign
diseas
older
inbr
mice
balbc
knockout
mice
stat
rag
beig
transgen
mice
develop
gener
ill
robust
viral
growth
pronounc
lung
patholog
consist
pneumonia
acut
lung
injuri
transgen
mice
develop
central
nervou
system
diseas
featur
human
inbr
mice
natur
suscept
infect
transduc
mice
develop
clinic
sign
support
replic
viru
interstiti
pneumonia
viral
antigen
found
lung
transgen
mice
develop
robust
respiratori
gener
ill
high
viral
titer
extens
inflamm
lung
lethal
also
observ
model
clinic
ill
measur
decreas
activ
exercis
wheel
accompani
viral
replic
pronounc
histopatholog
chang
inflamm
pneumon
consolid
lung
hamster
support
replic
clinic
ill
fever
sneez
accompani
viral
replic
histolog
chang
lung
ferret
support
replic
rabbit
model
investig
rabbit
model
current
investig
mouseadapt
sarscov
older
mice
result
model
ard
repres
stringent
challeng
evalu
vaccin
efficaci
either
alon
unfortun
immun
defect
associ
age
complex
influenc
result
vaccin
evalu
sever
anim
model
develop
sarslarg
crucial
domain
receptor
bind
sarscov
spike
protein
conserv
across
sever
speci
case
merscov
sever
point
mutat
protein
differ
anim
speci
limit
abil
merscov
spike
protein
attach
host
receptor
therefor
without
modif
either
receptor
viral
spike
protein
anim
model
mer
limit
nonhuman
primat
camel
recent
studi
shown
sequenc
homolog
rabbit
human
rais
possibl
rabbit
may
promis
model
merscov
infect
sever
sar
vaccin
candid
elicit
neutral
antibodi
effect
protect
young
mice
hamster
challeng
howev
report
immunopatholog
reaction
older
mice
nonhuman
primat
vaccin
sarscov
vaccin
subsequ
challeng
sarscov
reveal
two
concern
proceed
clinic
trial
sarscov
vaccin
first
preced
coronavirusvaccin
associ
diseas
enhanc
kitten
immun
vaccinia
viru
vector
felin
infecti
periton
viru
vaccin
develop
sever
diseas
subsequ
infect
fipv
kitten
nonneutr
subneutr
antibodi
facilit
viral
entri
macrophag
concern
extrapol
fipv
vaccin
experi
human
sarscov
vaccin
whether
vaccin
recipi
develop
sever
diseas
expos
infect
sarscov
neutral
antibodi
titer
declin
second
concern
whether
recipi
sarscov
vaccin
would
risk
develop
pulmonari
immunopatholog
follow
infect
unrel
human
coronaviru
exampl
usual
caus
mild
self
limit
diseas
although
find
preclin
evalu
reveal
concern
studi
anim
model
may
abl
provid
data
confirm
allay
concern
